These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 10231138

  • 1. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.
    Elmaagacli AH, Beelen DW, Trenn G, Schmidt O, Nahler M, Schaefer UW.
    Bone Marrow Transplant; 1999 Apr; 23(8):771-7. PubMed ID: 10231138
    [Abstract] [Full Text] [Related]

  • 2. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
    Min CK, Eom KS, Lee S, Kim DW, Lee JW, Min WS, Kim CC.
    Bone Marrow Transplant; 2001 May; 27(9):999-1005. PubMed ID: 11436112
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B, Majolino I, Dreger P, Scimè R, Santoro A, Vasta S, Suttorp M, Haferlach T, Schmitz N.
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [Abstract] [Full Text] [Related]

  • 4. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R.
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [Abstract] [Full Text] [Related]

  • 5. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL, Stainer C, Hyde H, Miflin G, Haynes AP, Bessell EM, Russell NH.
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [Abstract] [Full Text] [Related]

  • 6. Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation.
    Siegert W, Beyer J, Kingreen D, Blasczyk R, Baurmann H, Schwella N, Schleicher J, Kirsch A, Huhn D.
    Bone Marrow Transplant; 1998 Sep; 22(6):579-83. PubMed ID: 9758347
    [Abstract] [Full Text] [Related]

  • 7. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH, Runkel K, Steckel N, Opalka B, Trenschel R, Seeber S, Schaefer UW, Beelen DW.
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [Abstract] [Full Text] [Related]

  • 8. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ.
    Clin Cancer Res; 2004 Aug 01; 10(15):5065-71. PubMed ID: 15297408
    [Abstract] [Full Text] [Related]

  • 9. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
    Sun J, Meng FY, Liu QF, Xu D, Xu B, Liu XL.
    Ai Zheng; 2003 Dec 01; 22(12):1321-4. PubMed ID: 14693060
    [Abstract] [Full Text] [Related]

  • 10. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S, Nakao S, Ueda M, Yamazaki H, Takahashi S, Asano S, Yabe H, Kato S, Imoto S, Maruta A, Yoshida T, Gondo H, Morishima Y, Kodera Y.
    Bone Marrow Transplant; 2000 Oct 01; 26(7):769-74. PubMed ID: 11042659
    [Abstract] [Full Text] [Related]

  • 11. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF, Petersen EJ, Lokhorst HM, Nieuwenhuis HK, Dekker AW, Tilanus MG, de Weger RA.
    Bone Marrow Transplant; 1998 Dec 01; 22(11):1057-63. PubMed ID: 9877267
    [Abstract] [Full Text] [Related]

  • 12. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH.
    Biol Blood Marrow Transplant; 2004 Mar 01; 10(3):204-12. PubMed ID: 14993886
    [Abstract] [Full Text] [Related]

  • 13. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
    Barrett AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E, Dunbar C, Cottler-Fox M, Phang S, Carter C, Okunnieff P, Young NS, Read EJ.
    Bone Marrow Transplant; 1998 Mar 01; 21(6):543-51. PubMed ID: 9543057
    [Abstract] [Full Text] [Related]

  • 14. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
    de Lima M, van Besien K, Gajewski J, Khouri I, Andersson B, Korbling M, Champlin R, Giralt S.
    Bone Marrow Transplant; 2000 Aug 01; 26(3):333-8. PubMed ID: 10967575
    [Abstract] [Full Text] [Related]

  • 15. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
    de Lima M, Bonamino M, Vasconcelos Z, Colares M, Diamond H, Zalcberg I, Tavares R, Lerner D, Byington R, Bouzas L, da Matta J, Andrade C, Carvalho L, Pires V, Barone B, Maciel C, Tabak D.
    Bone Marrow Transplant; 2001 Jan 01; 27(1):73-8. PubMed ID: 11244440
    [Abstract] [Full Text] [Related]

  • 16. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
    Sanz Rodríguez C, Steegmann JL, Granda A, de la Cámara R, Figuera A, Arranz R, Gómez-García de Soria V, Alegre A, Fernández-Rañada JM.
    Sangre (Barc); 1999 Dec 01; 44(6):456-63. PubMed ID: 10822760
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation.
    Jabro G, Koc Y, Boyle T, Schenkein DP, Ravalese J, Wazer D, Miller KB.
    Biol Blood Marrow Transplant; 1999 Dec 01; 5(3):173-9. PubMed ID: 10392963
    [Abstract] [Full Text] [Related]

  • 19. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
    Liu QF, Sun J, Zhang Y, Liu XL, Xu D, Xu B, Feng R, Meng FY, Zhou SY.
    Ai Zheng; 2004 Apr 01; 23(4):426-9. PubMed ID: 15087032
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK, Parikh PM, Tawde S, Amare-Kadam PS, Rajadhyaksha S, Chhaya S.
    Natl Med J India; 2004 Apr 01; 17(2):71-3. PubMed ID: 15141598
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.